FOLGE 11: BEHANDLUNGSDAUER DES MULTIPLEN MYELOMS | Myelom-Grundlagen mit Prof. Hartmut Goldschmidt

In the eleventh episode of our series "Myeloma Basics," Prof. Dr. Hartmut Goldschmidt addresses the crucial question of treatment duration in multiple myeloma. How long should therapy be continued—and what factors determine the optimal time to change or discontinue treatment? Using current study data and guidelines, Prof. Goldschmidt examines the different phases of therapy, from induction and consolidation to maintenance therapy. He discusses the significance of response criteria, side effect profiles, and individual patient factors, and explains how treatment duration can be personalized. This episode provides practical guidance for decision-making in everyday clinical practice—a valuable resource for anyone deeply involved in treatment planning for multiple myeloma. About the Association "Myelom-heilen e.V." is a non-profit organization in Germany specializing in supporting patients with multiple myeloma and their families. The association was founded in 2018 and aims to improve the quality of life for myeloma patients and optimize their care. The association "Myelom-heilen e.V." offers a wide range of support and information services, including self-help groups, online forums, and informational events. The association also regularly organizes meetings for patients and their families, as well as seminars and training courses. In addition, the association is committed to promoting research into the treatment of multiple myeloma and improving therapy options for those affected. The association works closely with physicians and scientists to foster innovative treatment approaches and support the transfer of knowledge between patients and professionals. Furthermore, the association is an important resource for people living with multiple myeloma. The association offers support, information, and a sense of community for patients and their families and advocates for the needs and interests of myeloma patients to be heard in the public sphere. About the person Hartmut Goldschmidt is a German oncologist and hematologist who is a professor at the Department of Internal Medicine V at Heidelberg University Hospital. He specializes in the treatment of patients with multiple myeloma, a cancer that affects the bone marrow. Prof. Goldschmidt has conducted and published numerous clinical studies to develop better treatment options for patients with multiple myeloma. He is a member of several national and international professional societies and has received various awards for his work. Prof. Goldschmidt is also an experienced stem cell transplantation expert and has published numerous scientific papers on this topic. Furthermore, he is actively involved in the training of young physicians and researchers in the fields of oncology and hematology.